Affordable Access

Access to the full text

C3-glomerulonephritis in New Zealand – a case series

Authors
  • Sutherland, Luke J.1
  • Talreja, Hari2
  • 1 Auckland City Hospital, Auckland, New Zealand , Auckland (New Zealand)
  • 2 Middlemore Hospital, 100 Hospital Rd, Otahuhu, Auckland, 2025, New Zealand , Auckland (New Zealand)
Type
Published Article
Journal
BMC Nephrology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Sep 17, 2020
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s12882-020-02056-5
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundC3-glomerulonephritis can lead to progressive renal impairment from complement-mediated glomerular injury. Incidence and outcomes of C3-glomerulonephritis are not known in the New Zealand population.MethodsWe reviewed all cases of C3-glomerulonephritis from the past 10 years at a tertiary referral centre in New Zealand. Descriptive information on baseline characteristics and clinical outcomes was collected.ResultsTwenty-six patients were included (16 men; mean ± SD age 44 ± 25 years) with a median follow-up of 30 months. Disease incidence was 1.3 cases per million individuals, of which 42% were Pacific Islanders. Most patients presented with renal impairment, with a median (IQR) creatinine at diagnosis of 210 (146–300) μmol/L, and 11 (42%) patients presented with nephrotic syndrome. Seven (27%) patients progressed to end stage renal disease and 2 (8%) had died. End stage renal disease occurred in 20% of patients treated with immunosuppression and in 50% of those not treated. Complete remission was seen in 25% of patients treated with some form of immunosuppression and in 17% of those not treated.ConclusionsOur results are consistent with previous descriptions of C3-glomerulonephritis. There was a suggestion of better clinical outcomes in patients treated with immunosuppression. There was a higher disease incidence in Pacific Islanders, which may indicate an underlying susceptibility to complement dysfunction in this population.

Report this publication

Statistics

Seen <100 times